Gilead Sciences, Inc.
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. With each new discovery and experimental drug candidate, we seek to improve the care of patients suffering from life- threatening diseases around the world.
Gilead has a portfolio of 14 marketed products, including a number of category firsts, such as the first complete single tablet regimen for the treatment of HIV. The company developed and is currently commercializing two products for the treatment of chronic hepatitis B. Gilead‘s research and development program aims to identify and evaluate compounds that show potential to advance the treatment of life-threatening diseases in areas of unmet medical need. One of the company‘s most active areas of research is chronic hepatitis C, where the company is advancing multiple compounds in clinical development.